Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines

Patent metadata

Field	Value
Publication number	US-2026049115-A1
Application number	US-202519249789-A
Country	US
Kind code	A1
Filing date	Jun 25, 2025
Priority date	Mar 5, 2018
Publication date	Feb 19, 2026
Grant date	—

Abstract

The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra-or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

First claim

1 . A polypeptide comprising a cytokine polypeptide operatively linked to an extracellular matrix (ECM)-affinity peptide comprising a collagen binding domain, where the ECM-affinity peptide does not specifically bind fibronectin.

2 . The polypeptide of claim 1 , wherein the ECM-affinity peptide comprises a collagen binding domain of 100 to 350 amino acids of von Willebrand factor (vWF) or decorin.

3 . The polypeptide of claim 2 , wherein the vWF peptide is a vWF A1 or A3 peptide.

4 . The polypeptide of claim 2 , wherein the peptide is at least 85% identical to SEQ ID NO:3; SEQ ID NO:11; SEQ ID NO:13; SEQ ID NO:15, or SEQ ID NO:34.

5 . The polypeptide of claim 2 , wherein the peptide comprises SEQ ID NO:34.

6 . The polypeptide of claim 2 , wherein the vWF peptide comprises a peptide that is at least 85% identical to SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:34, or fragments thereof.

7 . The polypeptide of claim 6 , wherein the vWF peptide comprises SEQ ID NO:3 or SEQ ID NO:11 or SEQ ID NO:34.

8 . The polypeptide of claim 6 , wherein the vWF peptide consists essentially of SEQ ID NO:3 or SEQ ID NO:11 or SEQ ID NO:34.

9 . The polypeptide of claim 1 , wherein the peptide comprises a decorin peptide.

10 . The polypeptide of claim 9 , wherein the peptide comprises 10 to 200 consecutive amino acids of SEQ ID NO:15.

11 . The polypeptide of claim 9 or 10 , wherein the peptide is at least 85% identical to SEQ ID NO:15.

12 . The polypeptide of any one of claims 1-11 , wherein the peptide is covalently linked to the cytokine.

13 . The polypeptide of any one of claims 1-12 , wherein the peptide is crosslinked to the cytokine through a bifunctional crosslinker.

14 . The polypeptide of any one of claims 1-13 , wherein the cytokine is selected from IL-2, IL-15, IL-15 super agonist, IL-21, IL-12 p35, IL-12 p40, CCL4, CCL21, CXCL9, CXCL10, VEGF-C, IFNα2, IFNβ, XCL-1, or an active fragment thereof.

15 . The polypeptide of any one of claims 1-14 , wherein the cytokine is at least 85% identical to SEQ ID NO:37, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, or SEQ ID NO:46.

16 . The polypeptide of claim 13 or 15 , wherein the cytokine is IL-2.

17 . The polypeptide of any one of claims 1-16 , wherein the ratio of peptide to cytokine is about 1:1 to 10:1.

18 . The polypeptide of claim 1 , wherein the composition comprises an IL-2 cytokine operatively linked to vWF peptide.

19 . A nucleic acid vector comprising a heterologous coding region that encodes a polypeptide of any on of claims 1 to 18 .

20 . A composition comprising a polypeptide of any one of claims 1 to 18 comprised in a pharmaceutical formulation.

21 . The composition of claim 20 , further comprising at least one an anti-cancer compound.

22 . A method for treating cancer in a subject comprising administering the composition of any one of claims 1-18 to a subject.

23 . The method of claim 22 , wherein the composition is administered intravascularly, systemically or by intra-tumoral, peri-tumoral, intraarterial, or transcatheter injection.

24 . The method of claim 22 , wherein intravascularly is intravenously.

25 . The method of claim 22 or 23 or 24 , wherein the administered dose of the cytokine operatively linked to the peptide is less than the minimum effective dose of the cytokine administered without the peptide.

26 . The method of claim 25 , wherein the administered dose of the cytokine operatively linked to the peptide is at least 10% less than the minimum effective dose of the cytokine administered without the peptide.

27 . The method of any one of claims 22-26 , wherein the patient has been previously treated with a cancer immunotherapeutic.

28 . The method of any one of claims 22-26 , further comprising administering an anti-cancer therapeutic.

29 . The method of claim 27 , wherein the subject experienced grade two, three, or four side effects from the previous cancer therapeutic.

30 . The method of any one of claims 22-29 , wherein the subject has been diagnosed with a cancer.

31 . The method of any one of claims 22-30 , wherein the cancer comprises melanoma, colon cancer, lung cancer, prostate cancer, ovarian cancer, testicular cancer, brain cancer, glioblastoma, pediatric tumors, germ cell tumors, rectal cancer, gastric cancer, esophageal cancer, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, breast cancer, cervical cancer, and vulvar cancer.

32 . The method of claim 31 , wherein the cancer is melanoma or colon cancer.

33 . The method of any one of claims 22-30 , wherein the cancer is non-hematological.

34 . The method of any one of claims 22-33 , wherein the cancer comprises a solid tumor.

35 . The method of any one of claims 22-34 , wherein the method further comprises administration of an additional cancer therapy.

36 . The method of claim 35 , wherein the additional cancer therapy comprises radiation, vaccination, chemotherapy, adoptive T-cell therapy, cytokine therapy, anti-CD47 antibodies, anti-GD2 antibodies, or immunologic adjuvants.

37 . The method of claim 35 , wherein the polypeptide of any one of claims 1-18 is administered before, after, during, before and during, before and after, or during and after administration of anti-cacner therapeutic.

38 . The method of claim 35 or 36 , wherein the additional cancer therapy comprises one or more of MUC-1 inhibitors, CD40 activators, IDO inhibitors, and OX86 agonists.

39 . The method of claim 38 , wherein the additional cancer therapy comprises one or more of indoximod, GDC-0919, 1-methyl-D-tryptophan, norharmane hydrochloride, norharmane, CAY10581, INCB024360, and 2-benzyl-2-thiopseudourea hydrochloride.

40 . The method of any one of claim 22-39 , wherein the method further comprises administration of a second polypeptide comprising a cytokine operatively linked to a an extracellular matrix (ECM)-affinity peptide.

41 . The method of claim 40 , wherein a first and second polypeptide are administered together.

42 . The method of claim 41 , wherein the first and second polypeptide are co-formulated.

43 . A method of making a polypeptide of any one of claims 1 to 18 comprising expressing the polypeptide in a host cell and isolating the polypeptide expressed by the host cell.

44 . The method of claim 43 , wherein the host cell is a mammalian host cell.

45 . The method of claim 43 , wherein isolating the polypeptide comprises affinity column purification and/or size-exclusion column purification.

Assignees

• Univ Chicago

Inventors

• Hubbell Jeffrey A
• Ishihara Jun
• Ishihara Ako
• Sasaki Koichi
• Swartz Melody
• Mansurov Aslan

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K14/755 Primary

  Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)} · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/2013

  IL-2 · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title